Literature DB >> 11289754

nm23 protein expression in colorectal carcinoma metastasis in regional lymph nodes and the liver.

M Sarris1, C S Lee.   

Abstract

AIMS: The nm23 gene has been shown to have metastasis suppressing activity and abnormalities of the gene or its expression may be important in tumour progression and dissemination. This study was set out to investigate the possible role of the nm23 in colorectal adenocarcinoma dissemination by examining the level of nm23 protein expression in colorectal carcinoma metastasis in regional lymph nodes and the liver.
METHODS: Using a monoclonal antibody, NCL-nm23 (Novocastra), immunohistochemical expression of the nm23 protein was examined in cases of metastatic colorectal adenocarcinoma in regional lymph nodes (n=71) and liver (n=36).
RESULTS: The cases of lymph-node metastasis also had tissues from the primary carcinoma (n=71) and matching normal non-neoplastic mucosal tissues (n=71) from the colon and rectum available for the study. More than half of the cases of primary colorectal carcinoma (43/71; 60%) displayed strong nm23 immunoreactivity, with a similar proportion of the lymph-node metastases (40/71 cases; 56%) having strong nm23 immunostaining. However, only a small minority of the normal controls of non-neoplastic colorectal epithelia (12/71 cases; 17%) had strong nm23 immunoreactivity. The difference in nm23 protein expression between normal colorectal mucosa and primary colorectal carcinoma was statistically significant (P=0.0001; chi-squared test with continuity correction). However, no significant difference in nm23 protein expression was found between primary colorectal carcinoma and lymph-node metastases (P=0.81; chi-squared test with continuity correction). Most of the liver metastases (24/36 cases; 67%) had strong nm23 immunostaining but this finding was not statistically significant when compared with that seen in primary colorectal carcinoma (P=0.62; chi-squared test with continuity correction). In addition, nm23 expression was not found to significantly correlate with 5-year survival of patients with liver metastasis (P=0.86), suggesting that it had no predictive value for overall patient survival. There was also no significant correlation between disease recurrence and nm23 expression (P=0.63).
CONCLUSIONS: In summary, increased nm23 protein immunoreactivity is seen in the majority of colorectal carcinomas when compared to normal colorectal tissues but no significant difference in nm23 expression was found between primary colorectal carcinoma and metastatic carcinoma in regional lymph nodes or the liver. This study suggests that increased nm23 expression may be important in early colorectal carcinoma but not in later progression and dissemination of the tumour. In conclusion, the role and importance of the nm23 gene in the development of tumour metastasis in colorectal carcinoma is questionable. Copyright Harcourt Publishers Limited.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11289754     DOI: 10.1053/ejso.2000.1070

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  12 in total

1.  The intratumoral microvessel density and expression of bFGF and nm23-H1 in colorectal cancer.

Authors:  Sahande Elagoz; Reyhan Egilmez; Ayhan Koyuncu; Ahmet Muslehiddinoglu; Sema Arici
Journal:  Pathol Oncol Res       Date:  2006-03-23       Impact factor: 3.201

Review 2.  Clinical-translational approaches to the Nm23-H1 metastasis suppressor.

Authors:  Patricia S Steeg; Christine E Horak; Kathy D Miller
Journal:  Clin Cancer Res       Date:  2008-08-15       Impact factor: 12.531

Review 3.  Regulatory functions of Nm23-H2 in tumorigenesis: insights from biochemical to clinical perspectives.

Authors:  Yuanjun Li; Yao Tong; Yung H Wong
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2014-11-21       Impact factor: 3.000

4.  Antimetastatic role of Smad4 signaling in colorectal cancer.

Authors:  Bixiang Zhang; Sunil K Halder; Nilesh D Kashikar; Yong-Jig Cho; Arunima Datta; D Lee Gorden; Pran K Datta
Journal:  Gastroenterology       Date:  2009-11-10       Impact factor: 22.682

5.  Clinical-translational strategies for the elevation of Nm23-H1 metastasis suppressor gene expression.

Authors:  Jean-Claude Marshall; Jong Heun Lee; Patricia S Steeg
Journal:  Mol Cell Biochem       Date:  2009-04-23       Impact factor: 3.396

6.  NM23-H2 may play an indirect role in transcriptional activation of c-myc gene expression but does not cleave the nuclease hypersensitive element III(1).

Authors:  Thomas S Dexheimer; Steven S Carey; Song Zuohe; Vijay M Gokhale; Xiaohui Hu; Lauren B Murata; Estelle M Maes; Andrzej Weichsel; Daekyu Sun; Emmanuelle J Meuillet; William R Montfort; Laurence H Hurley
Journal:  Mol Cancer Ther       Date:  2009-05-12       Impact factor: 6.261

7.  NDPKA is not just a metastasis suppressor - be aware of its metastasis-promoting role in neuroblastoma.

Authors:  Choon-Yee Tan; Christina L Chang
Journal:  Lab Invest       Date:  2017-10-09       Impact factor: 5.662

8.  Does immunostaining effectively upstage colorectal cancer by identifying micrometastatic nodal disease?

Authors:  Khaled M Madbouly; Anthony J Senagore; Abir Mukerjee; Conor P Delaney; Jason Connor; Victor W Fazio
Journal:  Int J Colorectal Dis       Date:  2006-03-10       Impact factor: 2.571

9.  Reduced protein expression of metastasis-related genes (nm23, KISS1, KAI1 and p53) in lymph node and liver metastases of gastric cancer.

Authors:  Yu Guan-Zhen; Chen Ying; Ni Can-Rong; Wang Guo-Dong; Qian Jian-Xin; Wang Jie-Jun
Journal:  Int J Exp Pathol       Date:  2007-06       Impact factor: 1.925

Review 10.  Brain metastases from colorectal cancer: microenvironment and molecular mechanisms.

Authors:  Yi-Wen Zang; Xiao-Dong Gu; Jian-Bin Xiang; Zong-You Chen
Journal:  Int J Mol Sci       Date:  2012-11-26       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.